ZURA BIO LIMITED Payments to Acquire in Process Research and Development
ZURA BIO LIMITED (ZURA) reported Payments to Acquire in Process Research and Development of $5.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment · last filed 2026-03-19
- ZURA BIO LIMITED payments to acquire in process research and development for the quarter ending 2024-12-31 was $0.00.
- ZURA BIO LIMITED payments to acquire in process research and development for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ZURA BIO LIMITED payments to acquire in process research and development for the quarter ending 2024-06-30 was $0.00.
- ZURA BIO LIMITED payments to acquire in process research and development for the quarter ending 2024-03-31 was $5.00M.
- ZURA BIO LIMITED payments to acquire in process research and development for fiscal 2024 was $5.00M, a 37.50% decline from fiscal 2023.
- ZURA BIO LIMITED payments to acquire in process research and development for fiscal 2023 was $8.00M.
| Period end | Payments to Acquire in Process Research and Development 2 month | Payments to Acquire in Process Research and Development 3 month | Payments to Acquire in Process Research and Development 5 month | Payments to Acquire in Process Research and Development 6 month | Payments to Acquire in Process Research and Development 8 month | Payments to Acquire in Process Research and Development 9 month | Payments to Acquire in Process Research and Development 11 month | Payments to Acquire in Process Research and Development 12 month |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $5.00M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $5.00M 10-Q · filed 2025-11-13 | $5.00M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $5.00M 10-Q · filed 2025-08-14 | $5.00M derived: sum of 3 quarters · filed 2025-08-14 | $7.25M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $5.00M 10-Q · filed 2025-05-08 | $5.00M derived: sum of 2 quarters · filed 2025-05-08 | $7.25M derived: sum of 3 quarters · filed 2025-05-08 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $2.25M derived: sum of 2 quarters · filed 2025-03-25 | $8.00M 10-K · filed 2025-03-25 | |||||
| 2023-09-30 | $2.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $8.00M 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | $5.75M 10-Q · filed 2024-08-13 | |||||||
| 2022-12-31 | $12.00M 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | $5.00M 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | $5.00M 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | $5.00M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |